when amylin switched over in trade. let's switch over to another one.for respiratory drug has been delayed. several analyst downgrading the stock. we have rbc capitol. stock down better than 15%. lastly, optimer pharmaceuticals firing its ceo. now that news of course, scaring investors, that's why that stock is down 3.6%. scott, back to you. >> >>> thank you, seema. >>> steve forbes explains why he thinks the feds are doing more harm than good. do you agree with steve forbes? send a tweet to@cnbcclosingbell. we're back in a moment. [ shapiro ] at legalzoom, you can take care of virtually all your important legal matters in just minutes. now it's quicker and easier for you to start your business... protect your family... and launch your dreams. at legalzoom.com, we put the law on your side. introducing gold choice. the freedom you can only get from hertz to keep the car you reserved or simply choose another. and it's free. ya know, for whoever you are that day. it's just another way you'll be traveling at the speed of hertz. on december 21st polar shifts

look at shares of amylin, the third largest shareholder is carl, the man himself. >> netflix shares,harply lower. despite better than expected results. stock down about 14%. the company reporting it lost 8 cents a share in first quarter. an lift looki analysts looking for a loss of 27 cents. that loss topped out schmidt which called for revenue of 867 million. netflix adding 1.7 million streaming customers domestically. it was in line with the forecast but the stock nonetheless down almost 15%. get back to other big story of day today. major averages finishing the day lower but off of the worst levels of the session. it was clear that the spector of the eurozone debt worries continued to worry investors. we have apple reported earnings tomorrow night after the close. start after two-day federal reserve meeting tomorrow looking forward. what is the potential take away for investors? we welcome back scott ren, tim leach, also with me, is our cnbc all-stars, joining us, sue and mandy. scott, let me kick this off with you. let me get your take on the events of tomorrow. fed meeting, any

think a deal gets done and when it does get done it's going to be up at least high 30s so i think amylinld get a pop and someone will take them out. >> the best company in the space continues to be celgene. even with the move it's had that is a name you can hold. even with the stock up a hundred percent, human genome at 14 and change is still too cheap in my opinion. we would like it on the way up on the way down but a deal does get done and i think it is going to be significantly higher than where it is trading now 14 and change. >> just a week before the pharma company reports quarterly results. cnbc's herb greenburg is noticing interesting activity by analysts covering the stock. this is a herb alert. could move the stock. what are you hearing? >> michelle, when milan reports earnings next thursday keep an eye on how much it misses, meets, or beats. now look. i usually don't put much stock in this beat the street game, but this time is actually different. as i write on cnbc.com today, in recent weeks a handful of milan analysts cut their first quarter estimate numbers within days of o

amylin pharmaceutical is exploring a sale by reaching out to potential buyers.d from bristol myers and is fending off a lawsuit from an activist. beam and pinnacle -- beam is buying pinnacle vodka. and vodafone agrees to buy c & w worldwide for $1.9 billion. >> let's get a check on the markets which do not see this deal news as good. we've been right around this area here with the market -- >> i'm not sure it's the deal news as much as the earnings in europe. >> the market is not impressed by the deal news. we would opensharply lower this morning, more than 111 points. rick santelli standing by at the cme in chicago. rick, what has them troubled down there in the pits? let's see if we can solve their problems. >> well, there's no problems in life, there are only issues. when you say the market is opening down ignoring deals, i'm not watching the deals as closely as everybody at that desk but i like the statement to give us an idea about how to look at the market in general. for all we know, the stock market would have been three times or two times as much. we ju